Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
BridgeBio Pharma Inc (BBIO)
NASDAQ:BBIO
Holding BBIO?
Track your performance easily
BBIO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$21.62 - $41.04
Previous CloseN/A
Volume379.31K
Average Volume (3M)2.37M
Market Cap
$7.10B
Enterprise Value$6.14B
Total Cash (Recent Filing)$92.00M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Feb 20, 2025EPS Estimate
-1.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.41
Shares Outstanding188,989,800
10 Day Avg. Volume3,827,237
30 Day Avg. Volume2,366,995
Standard Deviation0.24
R-Squared0.06
Alpha0.00910
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)32.62
Price to Cash Flow (P/CF)-9.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue28.17
Enterprise Value/Gross Profit894.71
Enterprise Value/Ebitda-16.82
Forecast
1Y Price Target
$50.64Price Target Upside38.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
BridgeBio Pharma News
PremiumCompany Announcements
BridgeBio Pharma Reports Strong Drug Uptake and Trial Progress
Bulls Say, Bears Say
Bulls Say
Clinical Trials And DataBBP-418 and Encaleret PhIII data could drive upside, enhancing company prospects.
Product Launch SuccessEarly sales numbers for Attruby suggest the drug is off to a strong start in its launch.
Regulatory ApprovalsPotential EU and JP approvals could provide BBIO with $105M in milestones, accelerating growth.
Bears Say
Competitive LandscapeThe company's two key assets, acoramidis and infigratinib face competitive markets with entrenched players if both drugs are approved and commercialized.
Financial RiskMessy financials add further risk. BBIO has cash of $478M as of 06/30/24, and burns ~$200M/qrtr; $1.7B debt balance includes $1.3B converts due 2027/2029 to be refinanced in coming years.
Market DifferentiationThe lack of control beyond 30 weeks in the open-label extension period limits the ability to make valid comparisons with competing therapies.
---
Ownership Overview
20.77% Insiders
15.70% Mutual Funds
0.07% Other Institutional Investors
49.78% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BBIO FAQ
What was BridgeBio Pharma Inc’s price range in the past 12 months?
BridgeBio Pharma Inc lowest stock price was $21.62 and its highest was $41.04 in the past 12 months.
What is BridgeBio Pharma Inc’s market cap?
BridgeBio Pharma Inc’s market cap is $7.10B.
When is BridgeBio Pharma Inc’s upcoming earnings report date?
BridgeBio Pharma Inc’s upcoming earnings report date is Feb 20, 2025 which is in 20 days.
How were BridgeBio Pharma Inc’s earnings last quarter?
BridgeBio Pharma Inc released its earnings results on Nov 12, 2024. The company reported -$0.86 earnings per share for the quarter, beating the consensus estimate of -$1.003 by $0.143.
Is BridgeBio Pharma Inc overvalued?
According to Wall Street analysts BridgeBio Pharma Inc’s price is currently Undervalued.
Does BridgeBio Pharma Inc pay dividends?
BridgeBio Pharma Inc does not currently pay dividends.
What is BridgeBio Pharma Inc’s EPS estimate?
BridgeBio Pharma Inc’s EPS estimate is -1.13.
How many shares outstanding does BridgeBio Pharma Inc have?
BridgeBio Pharma Inc has 188,989,800 shares outstanding.
What happened to BridgeBio Pharma Inc’s price movement after its last earnings report?
BridgeBio Pharma Inc reported an EPS of -$0.86 in its last earnings report, beating expectations of -$1.003. Following the earnings report the stock price went down -5.743%.
Which hedge fund is a major shareholder of BridgeBio Pharma Inc?
Among the largest hedge funds holding BridgeBio Pharma Inc’s share is Viking Global Investors LP. It holds BridgeBio Pharma Inc’s shares valued at 640M.
---
BridgeBio Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.64 (38.89% Upside)
$50.64 (38.89% Upside)
Blogger Sentiment
Bullish
BBIO Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 5.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.72%
12-Months-Change
Fundamentals
Return on Equity
35.68%
Trailing 12-Months
Asset Growth
1.52%
Trailing 12-Months
Company Description
BridgeBio Pharma Inc
BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.
---
BBIO Stock 12 Month Forecast
Average Price Target
$50.64
▲(38.89% Upside)
Technical Analysis
Alnylam Pharma
―
Biogen
―
BioMarin Pharmaceutical
―
Regeneron
―
Vertex Pharmaceuticals
―
Best Analysts Covering BBIO
1 Year
1 Year Success Rate
12/15 ratings generated profit
1 Year Average Return
+34.68%
assigned a buy rating 2 days ago
Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +34.68% per trade.
---